Low HDL causes: Difference between revisions
Jump to navigation
Jump to search
Ochuko Ajari (talk | contribs) |
Ochuko Ajari (talk | contribs) |
||
| Line 130: | Line 130: | ||
===Causes in Alphabetical Order=== | ===Causes in Alphabetical Order=== | ||
{{MultiCol}} | {{MultiCol}} | ||
*[[Abdominal aortic aneurysm]] | *[[Abdominal aortic aneurysm]] <ref name="pmid20671656">{{cite journal| author=Takagi H, Manabe H, Kawai N, Goto SN, Umemoto T| title=Serum high-density and low-density lipoprotein cholesterol is associated with abdominal aortic aneurysm presence: a systematic review and meta-analysis. | journal=Int Angiol | year= 2010 | volume= 29 | issue= 4 | pages= 371-5 | pmid=20671656 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20671656 }} </ref> | ||
*[[Anabolic steroids]] | *[[Anabolic steroids]]<ref name="pmid20816133">{{cite journal| author=Achar S, Rostamian A, Narayan SM| title=Cardiac and metabolic effects of anabolic-androgenic steroid abuse on lipids, blood pressure, left ventricular dimensions, and rhythm. | journal=Am J Cardiol | year= 2010 | volume= 106 | issue= 6 | pages= 893-901 | pmid=20816133 | doi=10.1016/j.amjcard.2010.05.013 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20816133 }} </ref> | ||
*[[Androgens]] | *[[Androgens]] | ||
* | *Apo A-1 Giessen | ||
* | *Apo A-1 Marburg | ||
*[[Apo A-1 Milano]] | *[[Apo A-1 Milano]] | ||
* | *Apo A-1 Munster | ||
*Apolipoprotein C-II deficiency<ref name="BaggioManzato1986">{{cite journal|last1=Baggio|first1=G|last2=Manzato|first2=E|last3=Gabelli|first3=C|last4=Fellin|first4=R|last5=Martini|first5=S|last6=Enzi|first6=G B|last7=Verlato|first7=F|last8=Baiocchi|first8=M R|last9=Sprecher|first9=D L|last10=Kashyap|first10=M L|title=Apolipoprotein C-II deficiency syndrome. Clinical features, lipoprotein characterization, lipase activity, and correction of hypertriglyceridemia after apolipoprotein C-II administration in two affected patients.|journal=Journal of Clinical Investigation|volume=77|issue=2|year=1986|pages=520–527|issn=0021-9738|doi=10.1172/JCI112332}}</ref> | *Apolipoprotein C-II deficiency<ref name="BaggioManzato1986">{{cite journal|last1=Baggio|first1=G|last2=Manzato|first2=E|last3=Gabelli|first3=C|last4=Fellin|first4=R|last5=Martini|first5=S|last6=Enzi|first6=G B|last7=Verlato|first7=F|last8=Baiocchi|first8=M R|last9=Sprecher|first9=D L|last10=Kashyap|first10=M L|title=Apolipoprotein C-II deficiency syndrome. Clinical features, lipoprotein characterization, lipase activity, and correction of hypertriglyceridemia after apolipoprotein C-II administration in two affected patients.|journal=Journal of Clinical Investigation|volume=77|issue=2|year=1986|pages=520–527|issn=0021-9738|doi=10.1172/JCI112332}}</ref> | ||
*[[atazanavir|Atazanavir sulfate]] | *[[atazanavir|Atazanavir sulfate]] | ||
| Line 169: | Line 169: | ||
*[[Malabsorption]] | *[[Malabsorption]] | ||
*[[Malnutrition]] | *[[Malnutrition]] | ||
*[[Metabolic syndrome]] | *[[Metabolic syndrome]]<ref name="pmid14742767">{{cite journal| author=Ito MK| title=The metabolic syndrome: pathophysiology, clinical relevance, and use of niacin. | journal=Ann Pharmacother | year= 2004 | volume= 38 | issue= 2 | pages= 277-85 | pmid=14742767 | doi=10.1345/aph.1D218 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14742767 }} </ref> | ||
*[[Nephrotic syndrome]] | *[[Nephrotic syndrome]] | ||
*[[Niemann-Pick disease|Niemann-Pick disease type B]] | *[[Niemann-Pick disease|Niemann-Pick disease type B]] | ||
*[[Obesity]]<ref name="AshenBlumenthal2005">{{cite journal|last1=Ashen|first1=M. Dominique|last2=Blumenthal|first2=Roger S.|title=Low HDL Cholesterol Levels|journal=New England Journal of Medicine|volume=353|issue=12|year=2005|pages=1252–1260|issn=0028-4793|doi=10.1056/NEJMcp044370}}</ref> | *[[Obesity]]<ref name="AshenBlumenthal2005">{{cite journal|last1=Ashen|first1=M. Dominique|last2=Blumenthal|first2=Roger S.|title=Low HDL Cholesterol Levels|journal=New England Journal of Medicine|volume=353|issue=12|year=2005|pages=1252–1260|issn=0028-4793|doi=10.1056/NEJMcp044370}}</ref> | ||
*[[Physical inactivity]]<ref name="AshenBlumenthal2005">{{cite journal|last1=Ashen|first1=M. Dominique|last2=Blumenthal|first2=Roger S.|title=Low HDL Cholesterol Levels|journal=New England Journal of Medicine|volume=353|issue=12|year=2005|pages=1252–1260|issn=0028-4793|doi=10.1056/NEJMcp044370}}</ref> | *[[Physical inactivity]]<ref name="AshenBlumenthal2005">{{cite journal|last1=Ashen|first1=M. Dominique|last2=Blumenthal|first2=Roger S.|title=Low HDL Cholesterol Levels|journal=New England Journal of Medicine|volume=353|issue=12|year=2005|pages=1252–1260|issn=0028-4793|doi=10.1056/NEJMcp044370}}</ref> | ||
*[[Probucol]] | *[[Probucol]] <ref name="pmid19457483">{{cite journal| author=Yamashita S, Matsuzawa Y| title=Where are we with probucol: a new life for an old drug? | journal=Atherosclerosis | year= 2009 | volume= 207 | issue= 1 | pages= 16-23 | pmid=19457483 | doi=10.1016/j.atherosclerosis.2009.04.002 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19457483 }} </ref> | ||
*[[Progestins]] | *[[Progestins]] | ||
*[[Propranolol]] | *[[Propranolol]] | ||
| Line 185: | Line 185: | ||
*[[Thiazide diuretics]] | *[[Thiazide diuretics]] | ||
*[[Tibolone]] | *[[Tibolone]] | ||
*[[diabetes mellitus|Uncontrolled diabetes mellitus]] | *[[diabetes mellitus|Uncontrolled diabetes mellitus]] <ref name="pmid15265253">{{cite journal| author=Miller M, Dobs A, Yuan Z, Battisti WP, Borisute H, Palmisano J| title=Effectiveness of simvastatin therapy in raising HDL-C in patients with type 2 diabetes and low HDL-C. | journal=Curr Med Res Opin | year= 2004 | volume= 20 | issue= 7 | pages= 1087-94 | pmid=15265253 | doi=10.1185/030079904125004105 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15265253 }} </ref> | ||
*[[low-fat diet|Very low-fat diet]] | *[[low-fat diet|Very low-fat diet]] | ||
{{EndMultiCol}} | {{EndMultiCol}} | ||
Revision as of 19:18, 23 September 2013
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
Low HDL causes On the Web |
|
American Roentgen Ray Society Images of Low HDL causes |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ogheneochuko Ajari, MB.BS, MS [2]
Overview
Causes
Life Threatening Causes
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.
Common Causes
Causes by Organ System
| Cardiovascular | No underlying causes |
| Chemical/Poisoning | No underlying causes |
| Dental | No underlying causes |
| Dermatologic | No underlying causes |
| Drug Side Effect | No underlying causes |
| Ear Nose Throat | No underlying causes |
| Endocrine | No underlying causes |
| Environmental | No underlying causes |
| Gastroenterologic | No underlying causes |
| Genetic | No underlying causes |
| Hematologic | No underlying causes |
| Iatrogenic | No underlying causes |
| Infectious Disease | No underlying causes |
| Musculoskeletal/Orthopedic | No underlying causes |
| Neurologic | No underlying causes |
| Nutritional/Metabolic | No underlying causes |
| Obstetric/Gynecologic | No underlying causes |
| Oncologic | No underlying causes |
| Ophthalmologic | No underlying causes |
| Overdose/Toxicity | No underlying causes |
| Psychiatric | No underlying causes |
| Pulmonary | No underlying causes |
| Renal/Electrolyte | No underlying causes |
| Rheumatology/Immunology/Allergy | No underlying causes |
| Sexual | No underlying causes |
| Trauma | No underlying causes |
| Urologic | No underlying causes |
| Miscellaneous | No underlying causes |
Causes in Alphabetical Order
References
- ↑ Takagi H, Manabe H, Kawai N, Goto SN, Umemoto T (2010). "Serum high-density and low-density lipoprotein cholesterol is associated with abdominal aortic aneurysm presence: a systematic review and meta-analysis". Int Angiol. 29 (4): 371–5. PMID 20671656.
- ↑ Achar S, Rostamian A, Narayan SM (2010). "Cardiac and metabolic effects of anabolic-androgenic steroid abuse on lipids, blood pressure, left ventricular dimensions, and rhythm". Am J Cardiol. 106 (6): 893–901. doi:10.1016/j.amjcard.2010.05.013. PMID 20816133.
- ↑ Baggio, G; Manzato, E; Gabelli, C; Fellin, R; Martini, S; Enzi, G B; Verlato, F; Baiocchi, M R; Sprecher, D L; Kashyap, M L (1986). "Apolipoprotein C-II deficiency syndrome. Clinical features, lipoprotein characterization, lipase activity, and correction of hypertriglyceridemia after apolipoprotein C-II administration in two affected patients". Journal of Clinical Investigation. 77 (2): 520–527. doi:10.1172/JCI112332. ISSN 0021-9738.
- ↑ Huxley RR, Barzi F, Lam TH, Czernichow S, Fang X, Welborn T; et al. (2011). "Isolated low levels of high-density lipoprotein cholesterol are associated with an increased risk of coronary heart disease: an individual participant data meta-analysis of 23 studies in the Asia-Pacific region". Circulation. 124 (19): 2056–64. doi:10.1161/CIRCULATIONAHA.111.028373. PMID 21986289.
- ↑ Cuisinier-Raynal JC, Bire F, Clerc M, Bernard J, Sarrouy J (1990). "[Human malaria: dysglobulinemia-hypocholesterolemia syndrome]". Med Trop (Mars). 50 (1): 91–5. PMID 2366654.
- ↑ Musunuru K, Pirruccello JP, Do R, Peloso GM, Guiducci C, Sougnez C; et al. (2010). "Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia". N Engl J Med. 363 (23): 2220–7. doi:10.1056/NEJMoa1002926. PMC 3008575. PMID 20942659.
- ↑ Schaefer EJ, Ordovas JM, Law SW, Ghiselli G, Kashyap ML, Srivastava LS; et al. (1985). "Familial apolipoprotein A-I and C-III deficiency, variant II". J Lipid Res. 26 (9): 1089–101. PMID 3934306.
- ↑ Ito MK (2004). "The metabolic syndrome: pathophysiology, clinical relevance, and use of niacin". Ann Pharmacother. 38 (2): 277–85. doi:10.1345/aph.1D218. PMID 14742767.
- ↑ 9.0 9.1 9.2 Ashen, M. Dominique; Blumenthal, Roger S. (2005). "Low HDL Cholesterol Levels". New England Journal of Medicine. 353 (12): 1252–1260. doi:10.1056/NEJMcp044370. ISSN 0028-4793.
- ↑ Yamashita S, Matsuzawa Y (2009). "Where are we with probucol: a new life for an old drug?". Atherosclerosis. 207 (1): 16–23. doi:10.1016/j.atherosclerosis.2009.04.002. PMID 19457483.
- ↑ Miller M, Dobs A, Yuan Z, Battisti WP, Borisute H, Palmisano J (2004). "Effectiveness of simvastatin therapy in raising HDL-C in patients with type 2 diabetes and low HDL-C". Curr Med Res Opin. 20 (7): 1087–94. doi:10.1185/030079904125004105. PMID 15265253.